```html

Wegener’s Granulomas (ENT) – Comprehensive Medical Guide

Overview

Wegener’s granulomatosis, now more commonly called granulomatosis with polyangiitis (GPA), is a rare, systemic autoimmune disease characterized by inflammation of small‑ and medium‑sized blood vessels (vasculitis) and the formation of necrotic granulomas. When the disease involves the upper airway—nose, sinuses, middle ear, and throat—it presents as “Wegener’s granulomas (ENT).” These granulomatous lesions can cause chronic sinusitis, nasal crusting, otitis media, and subglottic stenosis.

• Incidence: Approximately 12–13 new cases per million people per year in the United States and Europe.
• Prevalence: Roughly 3 cases per 100,000 population worldwide.
• Age & Sex: Most commonly diagnosed between 40–60 years; slightly more common in males (1.4:1 ratio).
• Ethnicity: Higher rates have been reported in people of Northern European descent, but the disease occurs in all ethnic groups.

Symptoms

ENT manifestations may appear alone or together with lung, kidney, or systemic signs. The following list covers the full spectrum of ENT‑related symptoms, each with a brief description.

Nasal & Paranasal Symptoms

• Persistent nasal congestion – often unilateral, not relieved by typical decongestants.
• Crusting and ulceration – thick brown or yellow crusts that may bleed when removed.
• Epistaxis (nosebleeds) – recurrent or profuse bleeding due to mucosal erosion.
• Septal perforation – a hole in the nasal septum that can cause whistling or crusting.
• Loss of sense of smell (anosmia) – from chronic sinus inflammation.
• Facial pain or pressure – often mistaken for sinus infection.

Sinus & Nasal Cavity

• Recurrent or chronic sinusitis that does not respond to antibiotics.
• Sinus cavitation or bone destruction visible on imaging.

Ear (Otologic) Symptoms

• Otitis media with effusion – fluid behind the eardrum causing hearing loss.
• Conductive hearing loss – due to eustachian tube dysfunction or middle‑ear mass.
• Persistent ear pain or fullness.
• Otitis externa – inflammation of the ear canal, sometimes with granulation tissue.

Throat & Laryngeal Symptoms

• Hoarseness or voice change – from subglottic inflammation.
• Dyspnea on exertion – when subglottic stenosis narrows the airway.
• Sore throat – chronic, non‑infectious.
• Difficulty swallowing (dysphagia) – rare but reported when granulomas affect the pharynx.

Systemic Features (often accompany ENT disease)

• Fever, weight loss, fatigue.
• Joint pain (arthralgias) or arthritis.
• Kidney involvement (hematuria, proteinuria) – occurs in ~30 % of patients.
• Lung infiltrates or hemoptysis.

Causes and Risk Factors

GPA is an autoimmune vasculitis; its exact trigger is unknown, but research points to a combination of genetic predisposition and environmental exposures.

Pathophysiology

• ANCA antibodies – >90 % of patients have anti‑proteinase‑3 (PR3‑ANCA) antibodies that activate neutrophils, causing vessel damage and granuloma formation.
• Genetic factors – HLA‑DPB1*04:01 and certain PTX3 gene variants increase susceptibility.
• Environmental triggers – silica dust, chronic nasal infections, and possibly certain medications (e.g., propylthiouracil) have been implicated.

Who Is at Higher Risk?

• Adults aged 40‑60 years.
• Male sex (modest increase).
• Individuals with a family history of autoimmune disease.
• Occupational exposure to silica or combustible dust.
• Patients on certain drugs that can induce ANCA formation.

Diagnosis

Because GPA mimics common infections, a high index of suspicion is required. Diagnosis is multidisciplinary, involving ENT specialists, rheumatologists, pulmonologists, and nephrologists.

Clinical Evaluation

• Detailed history focusing on ENT symptoms, systemic features, and exposure risks.
• Physical exam – nasal endoscopy, otoscopy, and laryngoscopy to visualize granulomas, crusts, or subglottic narrowing.

Laboratory Tests

• ANCA testing – PR3‑ANCA (c‑ANCA) is positive in 70‑90 % of GPA cases; MPO‑ANCA (p‑ANCA) in a minority.
• Complete blood count (CBC) – may show anemia or leukocytosis.
• Renal function panel – serum creatinine, urinalysis for hematuria/proteinuria.
• Inflammatory markers – ESR and CRP are usually elevated.

Imaging

• CT of the sinuses – shows bone destruction, sinus opacification, and soft‑tissue masses.
• Chest CT – evaluates pulmonary nodules, infiltrates, or cavitations.
• MRI of the head/neck – useful for assessing soft‑tissue extension and subglottic stenosis.

Histopathology

Biopsy of nasal mucosa, sinus tissue, or middle‑ear granulation provides definitive evidence:

• Necrotizing granulomatous inflammation.
• Vasculitis of small‑ to medium‑size vessels.
• Absence of infection on special stains (Gram, PAS, acid‑fast).

Diagnostic Criteria

Most clinicians use the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria, which assign points for:

• Positive PR3‑ANCA.
• Typical ENT, pulmonary, or renal involvement.
• Biopsy‑proven granulomatous inflammation.

A score ≥5 classifies the patient as having GPA.

Treatment Options

Therapy aims to induce remission, prevent organ damage, and maintain long‑term control with the lowest possible drug toxicity.

Induction Therapy (to achieve remission)

• High‑dose glucocorticoids – Prednisone 1 mg/kg/day (usually 40‑60 mg) tapered over 4‑6 months. Intravenous methylprednisolone pulses (500‑1000 mg/day for 3 days) are used for severe ENT or airway obstruction.
• Rituximab – Anti‑CD20 monoclonal antibody, 375 mg/m² weekly × 4 weeks or 1 g on days 0 and 14. Preferred over cyclophosphamide for many patients because of lower toxicity.
• Cyclophosphamide – Oral (2 mg/kg/day) or IV (15 mg/kg every 2‑3 weeks) for 3‑6 months when rituximab isn’t suitable.
• Plasma exchange – Considered for rapidly progressive kidney disease or severe pulmonary hemorrhage; its benefit for isolated ENT disease is limited.

Maintenance Therapy (to prevent relapse)

• Rituximab 500 mg every 6 months for 2‑4 years.
• Aza­zathioprine 2‑3 mg/kg/day.
• Mycophenolate mofetil 1‑1.5 g twice daily (alternative for patients intolerant to azathioprine).
• Low‑dose prednisone (≤5 mg/day) while tapering.

Local ENT Interventions

• Nasal saline irrigation – helps clear crusts and reduce irritation.
• Topical mupirocin or silver nitrate – for localized ulcerated lesions.
• Endoscopic sinus surgery – indicated for refractory sinus disease, to debride necrotic tissue and improve ventilation.
• Tracheal dilation or laser resection – for subglottic stenosis causing airway obstruction.
• Ventilation tubes – for persistent middle‑ear effusion in children or adults.

Lifestyle & Supportive Measures

• Smoking cessation – smoking worsens sinonasal inflammation.
• Vaccinations – influenza, pneumococcal, COVID‑19; give before immunosuppression when possible.
• Bone health – calcium, vitamin D, and bisphosphonates if on prolonged steroids.
• Psychological support – chronic disease coping strategies, counseling.

Living with Wegener’s Granulomas (ENT)

Managing GPA is a lifelong partnership between you, your ENT specialist, and your rheumatology team.

Daily Self‑Care Tips

• Saline nasal rinses 2‑3 times daily with a sterile neti pot or squeeze bottle.
• Apply a thin layer of petroleum jelly or nasal moisturizer after rinsing to prevent crusting.
• Keep ears dry; use ear plugs while showering if you have middle‑ear disease.
• Maintain a medication calendar; never miss a dose of maintenance therapy.
• Track symptoms in a journal (nasal bleeding, hearing changes, voice changes) to detect early relapse.
• Stay hydrated and follow a low‑salt diet if you develop kidney involvement.

Monitoring Schedule

Visit Type	Frequency	Key Checks
Rheumatology	Every 3 months (first year) then every 6‑12 months	ANCA titers, CBC, renal labs, drug side‑effects
ENT	Every 6 months or sooner if symptoms change	Nasendoscopy, hearing test, airway exam
Primary Care	Annually	Blood pressure, vaccinations, bone density

Psychosocial Considerations

Living with a rare, potentially life‑threatening disease can cause anxiety and depression. Seek counseling, join patient support groups (e.g., Vasculitis Foundation), and discuss any mood changes with your care team.

Prevention

Because the exact cause of GPA is unknown, primary prevention is limited. However, some measures may lower the risk of disease flare or secondary complications:

• Avoid occupational silica exposure—use protective respirators.
• Promptly treat chronic nasal infections; don’t over‑use topical nasal decongestants.
• Quit smoking and limit alcohol, both of which can aggravate mucosal inflammation.
• Regularly update vaccinations before initiating immunosuppressive therapy.
• Stay vigilant for early ENT symptoms; early referral can prevent irreversible tissue damage.

Complications

If left untreated or inadequately controlled, GPA can cause permanent damage and life‑threatening events.

• Permanent nasal deformity – saddle‑nose due to cartilage loss.
• Chronic sinusitis with fungal superinfection.
• Hearing loss – conductive or sensorineural, sometimes irreversible.
• Subglottic stenosis – may require tracheostomy.
• Renal insufficiency or end‑stage kidney disease.
• Pulmonary hemorrhage or fibrosis.
• Increased risk of infections due to immunosuppression (e.g., opportunistic pneumonia, shingles).
• Medication toxicity – cyclophosphamide‑related bladder cancer, rituximab‑related hypogammaglobulinemia.

When to Seek Emergency Care

---

Sources: Mayo Clinic, National Institutes of Health (NIH) – Vasculitis Foundation, American College of Rheumatology (ACR) 2022 GPA Classification Criteria, CDC Immunization Guidelines, Cleveland Clinic, European League Against Rheumatism (EULAR) recommendations, peer‑reviewed journals (Annals of Rheumatic Diseases 2023; JAMA Otolaryngology–Head & Neck Surgery 2022).

```